Newcastle University owns 6,744,000 shares, 4.9% of E-Therapeutics, currently.
E-Therapeutics, a drug discovery and development company targeting cancer that is listed on the UK’s Alternative Investment Market, plans to raise £40m ($60m) by selling new shares at 32p each. Newcastle University owns 6,744,000 shares, 4.9% of E-Therapeutics, currently. Malcolm Young, a professor at Newcastle University and chief executive of E-Therapeutics, who owns 12.1% currently,…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
